ES2766623T3 - Usos de inhibidores etiquetados HSP90 - Google Patents

Usos de inhibidores etiquetados HSP90 Download PDF

Info

Publication number
ES2766623T3
ES2766623T3 ES17156149T ES17156149T ES2766623T3 ES 2766623 T3 ES2766623 T3 ES 2766623T3 ES 17156149 T ES17156149 T ES 17156149T ES 17156149 T ES17156149 T ES 17156149T ES 2766623 T3 ES2766623 T3 ES 2766623T3
Authority
ES
Spain
Prior art keywords
tumor
hsp90
hsp90 inhibitor
propyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17156149T
Other languages
English (en)
Spanish (es)
Inventor
Gabriela Chiosis
Nagavarakishore Pillarsetty
Jason S Lewis
Steven M Larson
Tony Taldone
Mary L Alpaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Memorial Sloan Kettering Cancer Center
Original Assignee
Cornell University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University, Memorial Sloan Kettering Cancer Center filed Critical Cornell University
Application granted granted Critical
Publication of ES2766623T3 publication Critical patent/ES2766623T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES17156149T 2011-07-08 2012-07-06 Usos de inhibidores etiquetados HSP90 Active ES2766623T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506010P 2011-07-08 2011-07-08

Publications (1)

Publication Number Publication Date
ES2766623T3 true ES2766623T3 (es) 2020-06-12

Family

ID=47506428

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17156149T Active ES2766623T3 (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados HSP90
ES12811358.6T Active ES2624982T3 (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados HSP90

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12811358.6T Active ES2624982T3 (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados HSP90

Country Status (13)

Country Link
US (4) US9555137B2 (enExample)
EP (3) EP2729806B1 (enExample)
JP (4) JP6054389B2 (enExample)
KR (2) KR102025142B1 (enExample)
CN (3) CN104081206B (enExample)
AU (3) AU2012282905B8 (enExample)
BR (1) BR112014000445A2 (enExample)
CA (2) CA2841069C (enExample)
DK (1) DK2729806T3 (enExample)
EA (1) EA201490230A1 (enExample)
ES (2) ES2766623T3 (enExample)
MX (2) MX2014000292A (enExample)
WO (2) WO2013009655A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
EP2729806B1 (en) * 2011-07-08 2017-02-22 Sloan-kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
CN103279964B (zh) * 2013-04-23 2015-10-28 浙江大学 一种基于prca的pet图像动态重建方法及系统
EA201690406A1 (ru) * 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
KR102325454B1 (ko) * 2013-12-23 2021-11-16 메모리얼 슬로안 케터링 캔서 센터 방사성표지화를 위한 방법 및 시약
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
KR20170052687A (ko) 2014-09-17 2017-05-12 메모리얼 슬로안-케터링 캔서 센터 Ｈｓｐ90-표적화된 염증 및 감염 영상화 및 치료
WO2017062520A1 (en) 2015-10-05 2017-04-13 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
ES2788856T3 (es) 2017-03-20 2020-10-23 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US11680283B2 (en) 2017-09-22 2023-06-20 University Of Washington In situ combinatorial labeling of cellular molecules
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CA3115315A1 (en) 2018-10-15 2020-04-23 Anthony A. HYMAN Compounds for treatment of diseases and methods of screening therefor
SG11202106690QA (en) 2019-02-08 2021-07-29 Dewpoint Therapeutics Inc Methods of characterizing condensate-associated characteristics of compounds and uses thereof
EP3969122A4 (en) * 2019-05-15 2024-01-17 Whitehead Institute For Biomedical Research METHODS OF CHARACTERIZATION AND METHODS OF USING AGENT-CONDENSATE INTERACTIONS
WO2021055644A1 (en) 2019-09-18 2021-03-25 Dewpoint Therapeutics, Inc. Methods of screening for condensate-associated specificity and uses thereof
MA57202B1 (fr) 2019-09-19 2025-09-30 Novo Nordisk Health Care Ag Compositions d'activation de la pyruvate kinase r (pkr)
JP7589935B2 (ja) * 2019-10-31 2024-11-26 キヤノンメディカルシステムズ株式会社 解析装置および解析プログラム
US20230357760A1 (en) * 2020-10-02 2023-11-09 The Trustees Of Dartmouth College Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113025715A (zh) * 2021-03-23 2021-06-25 中山大学附属第一医院 Hop在预测胃癌预后中的应用
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN116813622A (zh) * 2023-05-19 2023-09-29 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156111B2 (en) * 2001-07-16 2007-01-02 Akrion Technologies, Inc Megasonic cleaning using supersaturated cleaning solution
EP1519735A4 (en) * 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
WO2005012482A2 (en) * 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
WO2005021552A1 (en) 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
AU2004286307A1 (en) * 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
KR20080073711A (ko) * 2005-10-21 2008-08-11 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
US8318790B2 (en) * 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
WO2008070472A2 (en) 2006-11-27 2008-06-12 University Of Maryland, Baltimore Use of plasma hsp90 related to malignancy
CN101622349A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-21调节的基因和途径
CA2683822A1 (en) * 2007-04-13 2008-10-23 Pharmacyclics, Inc. Calcium flux as a pharmacoefficacy biomarker for inhibitors of histone deacetylase
US8466140B2 (en) * 2007-09-10 2013-06-18 University Of Massachusetts Mitochondria-targeted anti-tumor agents
EP2211913A4 (en) * 2007-10-12 2010-12-22 Transmolecular Inc SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
EP2224804A4 (en) * 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
CN102216775B (zh) * 2008-08-18 2014-04-16 马克斯·普朗克科学促进协会 对hsp90-抑制剂的易感性
CN108752280A (zh) * 2009-08-17 2018-11-06 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
WO2011044394A1 (en) * 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
JP2013510585A (ja) 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
CA2832530C (en) 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
NZ618062A (en) 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
EP2729806B1 (en) * 2011-07-08 2017-02-22 Sloan-kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
KR20170052687A (ko) 2014-09-17 2017-05-12 메모리얼 슬로안-케터링 캔서 센터 Ｈｓｐ90-표적화된 염증 및 감염 영상화 및 치료

Also Published As

Publication number Publication date
CN109374889A (zh) 2019-02-22
CA2841069C (en) 2021-11-23
AU2017204369A1 (en) 2017-07-20
JP6662759B2 (ja) 2020-03-11
CN104081203A (zh) 2014-10-01
ES2624982T3 (es) 2017-07-18
AU2012282905A8 (en) 2017-08-31
AU2017204369B2 (en) 2019-08-01
EA201490230A1 (ru) 2014-06-30
MX2014000286A (es) 2015-03-06
CN104081203B (zh) 2018-07-31
JP2014527620A (ja) 2014-10-16
KR20140075667A (ko) 2014-06-19
KR102025142B1 (ko) 2019-09-26
DK2729806T3 (en) 2017-05-15
JP2017121233A (ja) 2017-07-13
AU2012282905A1 (en) 2014-02-13
AU2012282903A1 (en) 2014-02-13
US11607465B2 (en) 2023-03-21
WO2013009657A1 (en) 2013-01-17
US9555137B2 (en) 2017-01-31
KR20170042805A (ko) 2017-04-19
US20140294725A1 (en) 2014-10-02
EP3208615A2 (en) 2017-08-23
CA2841173C (en) 2022-06-21
KR102138218B1 (ko) 2020-07-28
NZ620634A (en) 2016-07-29
EP2729806B1 (en) 2017-02-22
EP3208615B1 (en) 2019-10-09
EP2729806A4 (en) 2015-04-01
AU2012282905B2 (en) 2017-04-06
EP3709022A1 (en) 2020-09-16
US20140242602A1 (en) 2014-08-28
US20240058482A1 (en) 2024-02-22
CN104081206B (zh) 2017-06-09
CA2841069A1 (en) 2013-01-17
US20210138091A1 (en) 2021-05-13
HK1243175A1 (en) 2018-07-06
CN104081206A (zh) 2014-10-01
MX347607B (es) 2017-05-04
EP3208615A3 (en) 2017-11-01
JP2014525908A (ja) 2014-10-02
BR112014000445A2 (pt) 2017-06-27
WO2013009655A2 (en) 2013-01-17
JP6218147B2 (ja) 2017-10-25
MX2014000292A (es) 2015-03-06
JP6054389B2 (ja) 2016-12-27
AU2012282905B8 (en) 2017-08-31
WO2013009655A3 (en) 2013-05-10
CA2841173A1 (en) 2013-06-17
CN109374889B (zh) 2022-04-19
EP2729806A1 (en) 2014-05-14
JP2019194232A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
ES2766623T3 (es) Usos de inhibidores etiquetados HSP90
HK40039014A (en) Uses of labeled hsp90 inhibitors
Class et al. Patent application title: USES OF LABELED HSP90 INHIBITORS Inventors: Gabriela Chiosis (New York, NY, US) Gabriela Chiosis (New York, NY, US) Tony Taldone (New York, NY, US) Mary L. Alpaugh (Teaneck, NJ, US) Erica M. Gomes-Dagama (New Rochelle, NY, US) Monica L. Guzman (New York, NY, US) Hongliang Zong (New York, NY, US) Assignees: CORNELL UNIVERSITY SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
HK1243175B (en) Uses of labeled hsp90 inhibitors
HK1192943B (en) Uses of labeled hsp90 inhibitors
HK1192943A (en) Uses of labeled hsp90 inhibitors
NZ620634B2 (en) Uses of labeled hsp90 inhibitors